CTNND2: A Protein Potential Drug Target (G1501)

Target Name: CTNND2

NCBI ID: G1501

CTNND2

CTNND2: A Protein Potential Drug Target

CTNND2, also known as neurojungin, is a protein that is expressed in various tissues throughout the body, including the brain. It is a member of the neurojunctional protein family, which is a group of proteins that are involved in the formation and maintenance of neural connections.

Recent studies have identified CTNND2 as a potential drug target for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because CTNND2 has been shown to play a role in the formation of neural connections and in the regulation of neurotransmitter release, which are both important for the functioning of the brain.

One of the key reasons for the potential utility of CTNND2 as a drug target is its involvement in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. CTNND2 has been shown to play a role in the formation of new neural connections in the brain, as well as in the regulation of the strength and stability of existing connections. This means that CTNND2 could potentially be used to treat conditions where the brain is not functioning properly, such as Alzheimer's disease, Parkinson's disease, or depression.

Another potential use of CTNND2 as a drug target is its role in the regulation of neurotransmitter release. Neurotransmitters are chemical messengers that are used by the brain to communicate with other cells and to regulate various brain functions. CTNND2 has been shown to play a role in the regulation of neurotransmitter release, which could make it a useful target for treatments of disorders that are characterized by abnormal neurotransmitter levels or disruptions in neurotransmission.

In addition to its potential as a drug target, CTNND2 also has potential as a biomarker. This is because it is a protein that is expressed in various tissues throughout the body, including the brain. This means that it can be used as a marker for the presence of certain diseases or conditions, such as neurodegenerative disorders.

One of the key challenges in studying CTNND2 as a potential drug target is its complex structure and the difficulty of modifying it to produce specific effects. This is because CTNND2 is a large protein that is involved in many different cellular processes, and it is not clear how to specifically target the mechanisms that are responsible for its function. However, researchers are continuing to study CTNND2 and to develop new techniques for modifying it in order to investigate its potential as a drug target.

Overall, CTNND2 is a protein that has the potential to be a useful drug target for a variety of neurological and psychiatric disorders. Its involvement in the regulation of synaptic plasticity and neurotransmission, as well as its potential as a biomarker, make it an attractive target for further research. As research continues, it is likely that the full potential of CTNND2 will be discovered and its potential as a drug will be realized.

Protein Name: Catenin Delta 2

Functions: Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses (PubMed:25807484). Involved in the regulation of Wnt signaling (PubMed:25807484). It probably acts on beta-catenin turnover, facilitating beta-catenin interaction with GSK3B, phosphorylation, ubiquitination and degradation (By similarity). Functions as a transcriptional activator when bound to ZBTB33 (By similarity). May be involved in neuronal cell adhesion and tissue morphogenesis and integrity by regulating adhesion molecules

The "CTNND2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTNND2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets